Molbio Diagnostics Limited has released the transcript of its Earnings Call for the second quarter and first half of fiscal year 2027, held on November 05, 2026. The call detailed financial performance, including a revenue of INR667 crores for H1 FY27, and discussed strategic initiatives such as expansion into the veterinary segment, new product launches like Truepост™, Trueamp®, and Truecyte®, and ongoing R&D efforts aimed at broadening the company’s diagnostic portfolio and market reach.
Molbio Diagnostics Q2 & H1 FY27 Earnings Call Transcript Released
Molbio Diagnostics Limited shared the transcript of its Earnings Call pertaining to the results for the second quarter and the first half of fiscal year 2027. The call, which took place on November 05, 2026, provided insights into the company’s financial performance and strategic future plans.
Financial Highlights and Performance
During the call, it was reported that Molbio Diagnostics achieved a revenue from operations of INR667 crores for the first half of FY27, which is comparable to the INR680 crores reported in the same period last year. The company’s EBITDA for H1 FY27 stood at INR153 crores, representing a margin of 23%. The Profit After Tax (PAT) for H1 FY27 was INR60 crores. The management acknowledged a slight dip in the first half revenue primarily due to a one-month delay in rate contract negotiations with the government, which has since been resolved, with orders now being processed.
Strategic Growth Initiatives
Molbio Diagnostics is actively pursuing a multi-pronged growth strategy. This includes expanding its geographical footprint with a focus on export-oriented activities in the second half of the fiscal year. A significant development is the company’s strategic push into the veterinary diagnostics market. This segment will leverage existing platforms like Truenat for developing new veterinary-oriented assays, including tests for rabies and other common diseases in companion animals.
New Product Pipeline and Innovation
The company is also advancing its research and development pipeline with the imminent launch of several new products. Three key platforms were highlighted: Trueamp®, a multiplexing platform for testing multiple diseases from a single sample; Truecyte®, a product for point-of-care diagnostics offering cell morphology and CBC counts; and Truepoc™, a swab-based screening test designed for broader reach, particularly in hinterland areas. These platforms are expected to be launched through FY28 and are designed to address unmet clinical needs in both human and veterinary diagnostics.
Veterinary Segment Expansion
The company is building a new vertical for veterinary applications, aiming to offer point-of-care solutions directly to veterinary clinics. While the market is currently unorganized, Molbio sees a significant opportunity. Initial focus is on companion animals, with plans to expand to bovine and other species. The company anticipates these new products will contribute meaningfully to revenue from FY28 onwards.
Outlook and Guidance
Molbio Diagnostics reaffirmed its guidance of at least 25% top-line growth for the current fiscal year, targeting a 24% to 25% EBITDA margin. The management expressed confidence in meeting growth plans, emphasizing that the business is not linear and typically sees a stronger performance in the second half of the year (60% of business) compared to the first half (40%). The company continues to focus on strengthening its technology, expanding its global footprint, and exploring new verticals.
Source: BSE
